中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
9期
33-35
,共3页
皮炎,脂溢性%氢化可的松%他克莫司
皮炎,脂溢性%氫化可的鬆%他剋莫司
피염,지일성%경화가적송%타극막사
Dermatitis,seborrheic%Hydrocortisone%Tacrolimus
目的 对比观察0.1％他克莫司软膏与1％氢化可的松软膏治疗面部脂溢性皮炎的疗效和安全性.方法 选取70例面部脂溢性皮炎患者进行12周的研究.将患者按随机数字表法分为他克莫司组34例和氢化可的松组36例,分别使用0.1％他克莫司软膏和1％氢化可的松软膏涂抹患处皮肤,每日2次.于治疗后4、8、12周进行随访,记录皮损积分、药物剩余量,患者满意度,评价疗效并记录不良反应.结果 治疗后4、8、12周两组患者皮损积分与治疗前比较均明显下降[他克莫司组:(1.81±1.77)、(0.81±0.35)、(0.07±0.26)分比(14.81±2.52)分,氢化可的松组:(2.01±1.58)、(0.91±0.46)、(0.08±0.28)分比(16.42±2.15)分,P＜0.05],但同一时间点两组比较差异无统计学意义(P＞0.05)；他克莫司组有效率和氢化可的松组比较差异无统计学意义(P＞0.05)；他克莫司组治疗后4、8、12周药物剩余量均明显多于氢化可的松组,差异有统计学意义(P＜0.05)；两组患者均未出现严重不良反应,他克莫司组治疗后4、8、12周患者满意度均明显高于氢化可的松组[88.2％(30/34)比69.4％(25/36)、91.2％(31/34)比83.3％(30/36)、97.1％(33/34)比80.6％(29/36),P＜0.05].结论 与1％氢化可的松软膏比较,0.1％他克莫司软膏只需更少用量即可获得同样的疗效,0.1％他克莫司软膏治疗面部脂溢性皮炎更有优势.
目的 對比觀察0.1％他剋莫司軟膏與1％氫化可的鬆軟膏治療麵部脂溢性皮炎的療效和安全性.方法 選取70例麵部脂溢性皮炎患者進行12週的研究.將患者按隨機數字錶法分為他剋莫司組34例和氫化可的鬆組36例,分彆使用0.1％他剋莫司軟膏和1％氫化可的鬆軟膏塗抹患處皮膚,每日2次.于治療後4、8、12週進行隨訪,記錄皮損積分、藥物剩餘量,患者滿意度,評價療效併記錄不良反應.結果 治療後4、8、12週兩組患者皮損積分與治療前比較均明顯下降[他剋莫司組:(1.81±1.77)、(0.81±0.35)、(0.07±0.26)分比(14.81±2.52)分,氫化可的鬆組:(2.01±1.58)、(0.91±0.46)、(0.08±0.28)分比(16.42±2.15)分,P＜0.05],但同一時間點兩組比較差異無統計學意義(P＞0.05)；他剋莫司組有效率和氫化可的鬆組比較差異無統計學意義(P＞0.05)；他剋莫司組治療後4、8、12週藥物剩餘量均明顯多于氫化可的鬆組,差異有統計學意義(P＜0.05)；兩組患者均未齣現嚴重不良反應,他剋莫司組治療後4、8、12週患者滿意度均明顯高于氫化可的鬆組[88.2％(30/34)比69.4％(25/36)、91.2％(31/34)比83.3％(30/36)、97.1％(33/34)比80.6％(29/36),P＜0.05].結論 與1％氫化可的鬆軟膏比較,0.1％他剋莫司軟膏隻需更少用量即可穫得同樣的療效,0.1％他剋莫司軟膏治療麵部脂溢性皮炎更有優勢.
목적 대비관찰0.1％타극막사연고여1％경화가적송연고치료면부지일성피염적료효화안전성.방법 선취70례면부지일성피염환자진행12주적연구.장환자안수궤수자표법분위타극막사조34례화경화가적송조36례,분별사용0.1％타극막사연고화1％경화가적송연고도말환처피부,매일2차.우치료후4、8、12주진행수방,기록피손적분、약물잉여량,환자만의도,평개료효병기록불량반응.결과 치료후4、8、12주량조환자피손적분여치료전비교균명현하강[타극막사조:(1.81±1.77)、(0.81±0.35)、(0.07±0.26)분비(14.81±2.52)분,경화가적송조:(2.01±1.58)、(0.91±0.46)、(0.08±0.28)분비(16.42±2.15)분,P＜0.05],단동일시간점량조비교차이무통계학의의(P＞0.05)；타극막사조유효솔화경화가적송조비교차이무통계학의의(P＞0.05)；타극막사조치료후4、8、12주약물잉여량균명현다우경화가적송조,차이유통계학의의(P＜0.05)；량조환자균미출현엄중불량반응,타극막사조치료후4、8、12주환자만의도균명현고우경화가적송조[88.2％(30/34)비69.4％(25/36)、91.2％(31/34)비83.3％(30/36)、97.1％(33/34)비80.6％(29/36),P＜0.05].결론 여1％경화가적송연고비교,0.1％타극막사연고지수경소용량즉가획득동양적료효,0.1％타극막사연고치료면부지일성피염경유우세.
Objective To compare the efficacy and safety of facial seborrheic dermatitis treated with 0.1％ tacrolimus ointment and 1％ hydrocortisone ointment.Methods Seventy patients with facial seborrheic dermatitis were enrolled in a 12-week study.The patients were divided into tacrolimus group (34cases) and hydrocortisone group (36 cases) by table of random digit method,the 2 groups were treated with 0.1％ tacrolimus ointment or 1％ hydrocortisone ointment applied twice daily to symptomatic regions of the face.The skin injury score,drug residue,patient satisfaction,efficacy and adverse event were followed up after treatment of 4,8,12 weeks.Results The skin injury score in 2 groups after treatment of 4,8,12 weeks was significant lower than that before treatment [tacrolimus group:(1.81 ± 1.77),(0.81 ± 0.35),(0.07 ±0.26) scores vs.(14.81 ±2.52) scores,and hydrocortisone group:(2.01 ± 1.58),(0.91 ±0.46),(0.08 ±0.28) scores vs.(16.42 ± 2.15) scores,P ＜ 0.05],but there was no significant difference between 2 groups (P ＞0.05).There was no significant difference in effective rate between 2 groups (P ＞0.05).The drug residue of tacrolimus group was significantly more than that of hydrocortisone group (P ＜ 0.05).There was no severe adverse event in 2 groups.The patient satisfaction in tacrolimus group after treatment of 4,8,12 weeks was significantly higher than that in hydrocortisone group [88.2％ (30/34) vs.69.4％ (25/36),91.2％ (31/34)vs.83.3％ (30/36),97.1％ (33/34) vs.80.6％ (29/36),P ＜0.05].Conclusion The 0.1％ tacrolimus ointment requires significantly fewer applications compared with 1％ hydrocortisone ointment to achieve a comparable clinical response with facial seborrheic dermatitis.
